References
- Worth PH. Cyclophosphamide and the bladder. BMJ 1971; iii: 182
- Pedersen-Bjergaard J, Ersboll J, Hansen VL, Hansen VL, Sørensen BL, Christoffersen K, et al. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med 1988; 10: 1028–32
- Travis LB, Curtis RE, Glimelius B, Holowaty EJ, Van Leeuwen FE, Lynch CF, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 1995; 87: 524–30
- Pedersen-Bjergaard J, Jonsson V, Pedersen M, Hou-Jensen K. Leiomyosarcoma of the urinary bladder after cyclophosphamide. J Clin Oncol 1995; 13: 532–3
- Fernandes ET, Manivel JC, Reddy PK, Ercole CJ. Cyclophosphamide associated bladder cancer – a highly aggressive disease: analysis of 12 cases. J Urol 1996; 156: 1931–3
- Kaldor JM, Day NE, Kittelmann B, Pettersson F, Langmark F, Pedersen D, et al. Bladder tumours following chemotherapy and radiotherapy for ovarian cancer: a case–control study. Int J Cancer 1995; 63: 1–6
- Tanguay C, Harvey I, Houde M, Srigley JR, Tetu B. Leiomyosarcoma of the urinary bladder following cyclophosphamide therapy: report of two cases. Mod Pathol 2003; 16: 512–4
- Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer 2002; 100: 82–5
- Stillwell TJ, Benson RC, Jr. Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients. Cancer 1988; 61: 451–7
- Wong TM, Yeo W, Chan LW, Mok TS. Hemorrhagic pyelitis, ureteritis, and cystitis secondary to cyclophosphamide: case report and review of the literature. Gynecol Oncol 2000; 76: 223–5
- Kawamura J, Sakurai M, Tsukamoto K, Tochigi H. Leiomyosarcoma of the bladder eighteen years after cyclophosphamide therapy for retinoblastoma. Urol Int 1993; 51: 49–53
- Sigal SH, Tomaszewski JE, Brooks JJ, Wein A, LiVolsi VA. Carcinosarcoma of the bladder following long-term cyclophosphamide therapy. Arch Pathol Lab Med 1991; 115: 1049–51
- Povirk LF, Shuker DE. DNA damages and mutagenesis induced by nitrogen mustards. Mutat Res 1994; 318: 205–26
- Curren RD, Yang LL, Conklin PM, Grafstrom RC, Harris CC. Mutagenesis of xeroderma pigmentosum fibroblasts by acrolein. Mutat Res 1988; 209: 17–22
- Khan MA, Travis LB, Lynch CF, Soini Y, Hruszkewycz AM, Delgado RM, et al. P53 mutations in cyclophosphamide-associated bladder cancer. Cancer Epidemiol Biomarkers Prev 1998; 7: 397–403
- Spruck CH, Rideout WM, Olumi AF, Ohneseit PF, Yang AS, Tsai YC, et al. Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage. Cancer Res 1993; 53: 1162–6
- Warren W, Biggs PJ, el-Baz M, Ghoneim MA, Stratton MR, Venitt S. Mutations in the p53 gene in schistosomal bladder cancer: a study of 92 tumours from Egyptian patients and a comparison between mutational spectra from schistosomal and non-schistosomal urothelial tumours. Carcinogenesis (Lond) 1995; 16: 1181–9
- Capizzi RL. Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol 1996; 23: 2–17